Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation by Weller, Jamie et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Anticoagulation in Pediatric 
Extracorporeal Membrane 
Oxygenation
Jamie Weller, Lakshmi Raman, Ayesha Zia and Ali McMichael
Abstract
Anticoagulation during extracorporeal membrane oxygenation (ECMO) is 
necessary to prevent catastrophic circuit clotting, but significant morbidity and 
mortality continue to be attributed to hemorrhagic and thrombotic complications. 
Due to the inflammatory response from the extracorporeal circuit and develop-
mental hemostasis, anticoagulation can be challenging particularly for pediatric 
patients. Unfractionated heparin (UFH) is the gold standard anticoagulant used in 
ECMO, but there is an expanding area of research evaluating other anticoagulants, 
such as direct thrombin inhibitors. This chapter provides an overview of anticoagu-
lant options for pediatric patients on ECMO as well as describes the various tests 
used to monitor and titrate anticoagulation.
Keywords: extracorporeal membrane oxygenation, anticoagulation,  
unfractionated heparin, bivalirudin
1. Introduction
Anticoagulation during extracorporeal membrane oxygenation (ECMO) is 
necessary to prevent catastrophic circuit clotting, but it contributes to significant 
morbidity and mortality. The Extracorporeal Life Support Organization (ELSO) 
international registry shows a 24% increase in the number of patients placed 
on ECMO and a 55% growth of centers utilizing ECMO from 2009 to 2015 [1]. 
Although there has been rapid growth in ECMO around the world, pediatric 
mortality rates have remained static or even increased depending on the reason 
for cannulation [1]. In a multicenter study, Dalton et al. showed that 19–70% of 
patients had a bleeding event and 12–43% of pediatric patients had a thrombotic 
event while anticoagulated on ECMO [2]. With the increase in centers utilizing 
ECMO, anticoagulation has become an important area of research.
2. Overview of hemostasis
In order to discuss the intricacies of anticoagulation during ECMO, a basic under-
standing of the mechanisms required for hemostasis and the coagulation cascade is 
necessary (Figure 1). Hemostasis occurs by vascular constriction, platelet plug creation, 
and clot formation through fibrin [3]. The vasculature surrounding the damaged tissue 
constricts limiting blood flow to the area. Platelets adhere to the exposed endothelium 
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via von Willebrand factor creating a platelet plug to temporize the bleeding. Finally, the 
clotting cascade is activated by the presence of tissue factor released when blood vessels 
are damaged [3]. The clotting cascade has been traditionally described as the intrinsic 
and extrinsic pathways merging to initiate the common pathway, and resulting in the 
activation of fibrinogen to fibrin to form a stable clot. This classification is pertinent for 
understanding in vitro coagulation tests, but fails to account for the in vivo coagulation 
process [4, 5]. Current evidence suggests that the initial cascade augments the forma-
tion of thrombin through multiple feedback loops. The initiation phase is activated with 
exposure of tissue factor from damaged blood vessels. The initial amount of thrombin 
produced is insufficient to achieve adequate hemostasis, thus a series of feedback loops 
prompted by thrombin act to catalyze the factor (F) V and FVIII, eventually accelerat-
ing the activity of FXa and FIXa. This second phase is classified as the amplification 
phase [4]. The propagation phase ensures continued production of thrombin and thus 
fibrin, by forming sufficient prothrombinase complexes [4].
The hemostatic processes are counterbalanced by antithrombotic factors such as pro-
tein C, protein S, thrombomodulin, antithrombin, and tissue factor pathway inhibitor. 
Clot degradation is initiated by the fibrinolytic factors such as tissue plasminogen activa-
tor (tPA), plasminogen, and urokinase plasminogen activator [3]. The extracorporeal 
circuit interferes with the described mechanisms designed to achieve adequate hemosta-
sis. Immediately upon contact with the foreign ECMO circuit, the coagulation cascade is 
activated and a complex inflammatory response occurs [6]. Platelets, neutrophils, and 
leukocytes are activated along with thrombin and plasmin. Platelets adhere to the foreign 
surface leading to both platelet and factor consumption. Activated neutrophils contrib-
ute to the inflammatory response by producing cytokines. In addition, thrombin, FXa, 
and FVIIa cause complement activation further causing an inflammatory state. The end 
result is a consumptive state with disequilibrium of coagulation [7–10].
3. Anticoagulation with unfractionated heparin in ECMO
Although anticoagulation during ECMO is necessary to prevent circuit throm-
bosis and subsequent thromboembolic events in the patient, it continues to be a 
Figure 1. 
In vivo concept of coagulation. The clotting system is classified into the initiation, amplification, and propagation 
phase. TF, tissue factor (thromboplastin); II, prothrombin; I, fibrinogen.
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significant risk factor for complications in ECMO patients. The most common bleed-
ing complications during ECMO include intracranial hemorrhage (ICH), surgical 
site bleeding, and gastrointestinal hemorrhage (Table 1). Surgical site bleeding is the 
most frequent complication and occurs in up to 25% of pediatric cardiac and respira-
tory ECMO patients [1]. Bleeding events are associated with increased mortality [2]. 
For example, while ICH is not a frequent complication, the effect is significant with a 
survival rate of 17–40% compared to 45–68% for those who do not have an ICH [1]. 
In addition to hemorrhage, thrombotic complications can occur. While not as com-
mon as bleeding complications, cerebral infarcts accounted for 3–7% of complica-
tions described in the ELSO registry report [1]. Unfractionated heparin continues to 
be the most widely studied and used anticoagulant for anticoagulation in ECMO, but 
alternative agents are increasingly being used in pediatric and adult ECMO patients.
3.1 Unfractionated heparin
Unfractionated heparin (UFH) is the gold standard anticoagulant during ECMO 
and is commonly used in ECMO centers worldwide. Heparin acts as a catalyst 
to potentiate the action of antithrombin III, inhibiting thrombin and activated 
coagulation factor X, thus inhibiting the conversion of fibrinogen to fibrin [11]. 
The half-life of heparin is approximately 1–2 hours in healthy adults, but can vary 
significantly in pediatric patients. Heparin is metabolized by the reticuloendothelial 
system in the liver and spleen, and is excreted in the urine [11]. In the pediatric 
population, developmental hemostasis and the patient’s age may affect the pharma-
cokinetics of heparin [12]. For example, the neonatal population frequently requires 
additional monitoring and higher bolus and infusion rates to obtain effective 
anticoagulation [6, 12–14]. Another complication due to unfractionated heparin use 
is heparin-induced thrombocytopenia that is seen in 1–2% of pediatric patients [11].
For patients with preexisting conditions that preclude them from safe antico-
agulation, such as trauma patients with intracranial hemorrhage or patients that 
develop hemorrhagic complications while on ECMO, successful use of heparin-free 
ECMO management with or without heparin-bonded circuits has been documented 
[15–17]. However, the published literature is limited primarily to specific popula-
tions and for a limited duration of time.
4. Monitoring during heparin anticoagulation
Close monitoring to ensure anticoagulation is therapeutic is necessary to 
decrease the risk of hemorrhage or thrombosis during ECMO. The common tests 
used to monitor heparin during ECMO are activated clotting time (ACT), activated 
partial thromboplastin time (aPTT), and anti-factor Xa. No single test has been 
ICH 
N(%)






Neonatal cardiac 326(11) 739(26) 35(1) 93(3)
Neonatal respiratory 643(11) 386(7) 89(2) 180(3)
Pediatric cardiac 251(6) 974(25) 79(2) 231(6)
Pediatric respiratory 243(5) 332(10) 135(4) 158(7)
Table 1. 
Patient-related hemorrhagic and thrombotic complications extrapolated from the ELSO registry, 2009–2015 [1]. 
ICH, intracranial hemorrhage; GI, gastrointestinal.
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found to be superior to monitor heparin during ECMO. ECMO centers worldwide 
vary in their practices on the type of test or combination of tests used to monitor 
heparin [2, 18].
4.1 Activated clotting time
The activated clotting time (ACT) is a whole blood test used at the bedside that 
provides immediate results [3, 6]. The ACT measures the time in seconds to form 
a fibrin clot after the addition of specific coagulation activators, thus it does not 
solely measure the effect of unfractionated heparin. It is a relatively inexpensive 
test that has been widely used to monitor heparin during cardiopulmonary bypass, 
but coagulation factor deficiencies, hemodilution, platelet function, and hypofibri-
nogenemia may affect the value [3, 19]. Due to these limitations in ACT, Baird and 
colleagues retrospectively reviewed 600 pediatric ECMO patients and found only 
a modest correlation between ACT and UFH dose suggesting that ACT may not be 
an accurate tool for monitoring UFH anticoagulation [20]. Bembea and colleagues 
found similar results to Baird with only a 42% correlation between target ACTs and 
anti-factor Xa [21].
4.2 Activated partial thromboplastin time
Activated partial thromboplastin time (aPTT) is a plasma-based test, instead 
of a whole blood test, which only measures the initial 5% of thrombin generated 
and without incorporating platelet function or assessing clot strength. The aPTT 
measures the time from FXII activation to fibrin formation after addition of the 
PTT reagent and calcium [3, 19]. The therapeutic range for aPTT in adults has been 
shown to correlate to 1.5–2.5× the patient’s baseline aPTT [22]. However, this range 
has not been validated in pediatric patients and can vary significantly compared to 
adults. For example, an aPTT that correlates to anti-factor Xa between 0.35 IU/ml 
and 0.7 IU/ml in a patient less than 1 year old is between 58 and 105 seconds, but 
in a patient 6–10 years old the anti-factor Xa correlates to an aPTT between 45 and 
251 seconds [23]. The results of aPTT can be affected by fibrinogen level, presence 
of acute phase reactants, and increased levels of FVIII. These variables are often 
skewed in critically ill patients, which can lead to a high degree of intra- and inter-
patient variability [19].
4.3 Anti-factor Xa assay
The anti-Xa assay is a plasma-based test that measures the ability of UFH to 
catalyze antithrombin’s inhibition of factor Xa. Anti-Xa assay differs from ACT and 
aPTT as it measures the heparin concentration in the patient’s blood [24]. Since the 
anti-Xa assay only measures one specific action of heparin, the value is used as a 
surrogate to approximate overall function [19]. The anti-Xa value may be affected in 
patients with elevated plasma-free hemoglobin, hyperbilirubinemia, hypertriglyc-
eridemia, and antithrombin (depending on test reagants). A point of care anti-Xa 
test is available, but it is currently not widely used. Anti-factor Xa has been shown 
to have improved correlation to heparin activity as compared to aPTT and ACT 
[25]. In addition, a retrospective review of 62 pediatric ECMO patients with a mean 
anti-factor Xa level >0.2 IU/ml was associated with decreased circuit change [26].
Published literature supports the correlation between anti-factor Xa values and 
UFH dose. Unfortunately, many studies have shown a poor correlation between 
anti-factor Xa and ACT and/or aPTT. Multiple cardiac studies evaluating patients 
5Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation
DOI: http://dx.doi.org/10.5772/intechopen.85104
requiring cardiopulmonary bypass report disparities between ACT values and 
anti-Xa as compared to UFH doses [27–30]. ECMO adult studies have shown an 
improved correlation between aPTT and UFH concentrations, but pediatric studies 
demonstrate poor correlation to anti-factor Xa levels [31–33].
4.4 Viscoelastic testing
Viscoelastic testing such as thromboelastography (TEG) and rotational throm-
boelastometry (ROTEM) are whole blood tests that measure the interaction of 
clotting factors, fibrinogen, and platelets as well as fibrinolysis (Figure 2). By mea-
suring more than clotting factors, viscoelastic tests can give a more global picture 
of the coagulation system and allow for tailored transfusion management [3, 19]. 
Figure 2 shows the standard TEG measurements including reaction time (R), kinet-
ics (K), and maximum amplitude (MA). The R value is the time necessary for the 
initial clot formation. This value can be affected by the presence of anticoagulants, 
factor deficiencies, and hypercoagulable states. The K value measures the time for 
the clot to strengthen and can be affected by platelet count, fibrinogen, and coagu-
lation factors. The maximum amplitude quantifies the final strength of the clot. 
Overall clot strength can be affected by the amount and function of fibrinogen and 
platelets [3]. In general, viscoelastic tests can be limited by static flow conditions 
[19]. While there is limited evidence in trauma, obstetrics, liver transplantation, 
and hemophilia using viscoelastic testing to help define coagulopathy and decrease 
overall blood product transfusions, studies are needed to confirm these results in 
ECMO patients [34]. Furthermore, prospective studies should examine the use of 
TEG and ROTEM in conjunction with aPTT and/or anti-factor Xa.
Figure 2. 
Thromboelastography (TEG). R, reaction time; K, kinetics; MA, maximum amplitude; LY30, amplitude at 
30 minutes.
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5. Direct thrombin inhibitors
5.1 Bivalirudin
Alternative agents, such as direct thrombin inhibitors (DTI), have been increas-
ingly used in ECMO centers worldwide. Bivalirudin is a DTI that binds to both circu-
lating and clot-bound thrombin [35]. The basic structure of thrombin consists of the 
active site, exosite 1, and exosite 2. Exosite 1 is the location where specific substrates, 
such as fibrin, can bind and orient peptide bonds toward the active site of thrombin 
[36]. Bivalirudin is a bivalent DTI that blocks thrombin at the active site and exosite 
1 [36, 37]. Bivalirudin is primarily metabolized by proteolytic enzymes with 20% 
renally excreted [36]. With limited evidence to support the safety and therapeutic 
profile of bivalirudin in patients undergoing ECMO, bivalirudin has primarily been 
used in patients unresponsive to unfractionated heparin or those who developed 
heparin-induced thrombocytopenia [38]. In in vitro studies, bivalirudin inhibits both 
soluble and clot-bound thrombin, a unique mechanism of action not known to occur 
with unfractionated heparin [35]. Two prospective studies assessing clot resolution 
found that patients anticoagulated with bivalirudin for the treatment of deep vein 
thrombosis (DVT) had complete or partial clot resolution within 48 hours [39, 40].
5.2 Argatroban
Argatroban is a L-arginine derivative that reversibly binds and inhibits throm-
bin. Argatroban is a univalent DTI that binds solely to the active site of thrombin. 
It is metabolized by hepatic CYP3A4/5 oxidases and is excreted primarily in the 
feces [36, 41, 42]. Menk and colleagues retrospectively reviewed 78 adult patients 
with acute respiratory distress syndrome (ARDS) on ECMO. The single center 
study supported that patients anticoagulated with argatroban had no difference in 
major or minor bleeding and had more goal aPTT values compared to UFH con-
trols [43]. Multiple studies have shown that doses vary widely between adult and 
pediatric patients anticoagulated with argatroban on ECMO, thus careful monitor-
ing is imperative to ensure optimal anticoagulation [43–45]. A literature analysis 
reviewed nine articles describing 34 patients anticoagulated with argatroban. 
Pediatric patients were administered a dose ranging from 0.1 to 12 mcg/kg/min to 
achieve therapeutic anticoagulation. There was no correlation between the dose of 
argatroban and the age of the patient [45].
Bivalirudin and argatroban remain the most commonly utilized direct thrombin 
inhibitors for anticoagulation during ECMO, but small case studies have evaluated 
the efficacy of lepirudin [46, 47]. Unfortunately, the product is no longer available 
due to production discontinuation by the manufacturer.
5.3 Direct thrombin inhibitor use in ECMO
Disadvantages of DTIs include limited availability of laboratory monitoring spe-
cific to DTIs and lack of antidote. Currently, most centers that use DTIs follow aPTT 
for monitoring, which as mentioned previously can be affected by several patient 
variables. Ecarin chromogenic assay and dilute thrombin time are possible superior 
tests for monitoring, but are currently not widely available [36]. Unlike heparin, 
which can be reversed with protamine, no antidote exists for DTIs, but recombinant 
factor VIIa has been shown to be an effective reversal agent [48]. Plasmapheresis has 
also been shown to be effective in clearing bivalirudin, but limited evidence has been 
published supporting its use. An advantage of bivalirudin over argatroban is that it 
can be quickly removed by continuous renal replacement therapy [49].
7© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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Evidence of DTIs for ECMO patients is limited to case series or retrospective 
analyses. To confirm the safety and efficacy of DTIs and superiority (or at least non-
inferiority) to heparin, prospective randomized trials of pediatric and adult patients 
are needed. Two randomized studies are currently enrolling to compare bivalirudin 
to UFH for pediatric and adult ECMO patients (NCT03318393 and NCT03707418).
6. Nitric oxide
At present, systemic anticoagulation is the primary method to prevent thrombus 
formation during ECMO, but the use of nitric oxide within the extracorporeal 
circuit may be used to inhibit platelet adhesion. Nitric oxide (NO) is an endogenous 
substance released by the endothelial cells. NO temporarily inactivates platelets 
resulting in decreased function and aggregation [50, 51]. However, the effect of NO 
only temporarily inhibits platelets and after rapid degradation of NO by hemopro-
teins, platelets will regain normal function [52]. The utility of NO within ECMO 
circuits to limit or negate the requirement of systemic anticoagulation remains a 
promising area of research, but further studies to evaluate the long-term risks of 
thrombosis are warranted.
7. Conclusion
In summary, while the goal for ECMO anticoagulation is to prevent clinically sig-
nificant bleeding and clotting, the morbidity and mortality for these complications 
remain high for pediatric patients. Unfractionated heparin continues to be the most 
commonly used anticoagulant for ECMO patients in spite of its many disadvantages 
including altered pharmacokinetics in children and difficulty in lab monitoring. 
While there is a large variation between lab monitoring of heparin among ECMO 
centers, combination testing with anti-factor Xa and/or aPTT with viscoelastic tests 
is potentially superior. DTIs such as bivalirudin and argatroban remain promising 
alternatives to heparin, but prospective studies are needed to confirm their safety 
and efficacy.
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